Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Conditions
Brief summary
The purpose of this study is to find a new way to treat Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). All the drugs are used to treat AML and MDS but are not usually combined together. The investigators are looking at both the safety and Efficacy of each combination.
Detailed description
Study Groups: If the participant is found to be eligible to take part in this study and he/she is one of the first 30 participants enrolled, the participant will have an equal chance of being in one of 3 study groups. If the participant enrolls after the first 30 participants are enrolled, he/she will have a higher chance of being assigned to the group is having better results. * If participant is in Group 1, he/she will receive decitabine alone. * If participant is in Group 2, he/she will receive decitabine and carboplatin. * If participant is in Group 3, he/she will receive decitabine and arsenic trioxide. Study Drug Administration: Every 4 weeks is a study cycle. The participant will receive decitabine by vein over about 1 hours on Days 1-5 of each cycle. If the participant is receiving carboplatin, he/she will receive it over 1 hour on Day 8 (+/-2 days) of each cycle. If the participant is receiving arsenic trioxide, he/she will receive it over about 1 hour on Days 1-5 of each cycle Study Visits: Blood (about 1-2 teaspoons) will be drawn 1-2 times a week during Cycle 1 and then every 2-4 weeks after that for routine tests. If you have stable disease, blood will only be drawn every 4-6 weeks. On Day 28 of Cycle 3 (+/- 3 days), the participant will have a bone marrow aspirate and biopsy to check the status of the disease. After that, the participant will have bone marrow biopsies/aspirations when the doctor thinks it is needed. If the participant is in Group 3, he/she will have EKGs on Day 1 of each cycle before receiving the study drugs. On Days 1 and 4 of each cycle, blood (about 1-2 teaspoons) will also be drawn for routine tests before their dose of the study drugs. If the participant is taken off study, blood (about 1-2 teaspoons) will be drawn for routine tests. Length of Study: The participant may continue taking the study drugs for as long as the doctor thinks it is in your best interest. The participant will no longer be able to take the study drug(s) if the disease gets worse, if intolerable side effects occur, or if he/she is unable to follow study directions. This is an investigational study. Arsenic trioxide is FDA approved and commercially available for the treatment of APL. Decitabine is FDA approved and commercially available for the treatment of MDS. Carboplatin is FDA approved and commercially available for the treatment solid tumors. The study drug or study drug combination the participant receives on this study are considered investigational.
Interventions
DRUGDecitabine
20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
DRUGCarboplatin
AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
DRUGArsenic trioxide
0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
Sponsors
M.D. Anderson Cancer Center
Teva Pharmaceuticals USA
Fox Chase Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with AML, relapsed or refractory to standard therapy or elderly patients with AML (age 65 or over). Patients who have AML and are younger than age 65 but considered unfit for conventional chemotherapy are eligible. Patients with de novo or treated MDS or CMML INT-1 or above are eligible. Patients may have had prior exposure to azacitidine but no more than one cycle of decitabine. Patients must have been off chemotherapy for 2 weeks prior to entering this study and have recovered from the toxicities of that therapy; A caveat to this is in the case of rapidly progressive disease. Hydroxyurea is permitted for control of elevated WBC prior to treatment and can be continued for the first 4 weeks of therapy. Erythropoiesis stimulating agents (ESAs) and GCSF are allowed before therapy. ESAs, GCSF or other growth factors are permitted on therapy. 2. Performance 0-2 (ECOG). 3. Adequate cardiac functions assessed by 2D ECHO (NYHA cardiac III-IV excluded). 4. Pre-treatment EKG 5. Adequate end organ function with creatinine \</= 2mg/dL and total bilirubin \</= 2mg/dL, AST and ALT \</= or = 2.5 X institutional ULN. 6. Absence of significant intercurrent illness such as uncontrolled heart failure, unstable angina, cardiac arrhythmia and psychiatric illness which precludes the giving of informed consent. 7. Signed informed consent
Exclusion criteria
1. Nursing and pregnant females. Patients of childbearing potential should practice effective methods of contraception. Should a woman become preg-nant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 2. Current uncontrolled infections. 3. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements. 4. Chronic kidney disease \> stage 3. 5. HIV infection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to complete or partial remission | up to 16 weeks | evaluation of the complete and partial response rates (antileukemic effect) and the amount of time taken to achieve the response. |
Countries
United States
Outcome results
None listed